
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1432576/publications.pdf Version: 2024-02-01



CEDMAN OTT

#	Article	IF	CITATIONS
1	Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood, 2004, 103, 275-282.	1.4	3,574
2	The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell Lymphoma. New England Journal of Medicine, 2002, 346, 1937-1947.	27.0	3,474
3	Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma. New England Journal of Medicine, 2018, 378, 1396-1407.	27.0	1,443
4	Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature, 2010, 463, 88-92.	27.8	1,402
5	Oncogenically active MYD88 mutations in human lymphoma. Nature, 2011, 470, 115-119.	27.8	1,292
6	The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia, 2022, 36, 1720-1748.	7.2	1,023
7	A Biologic Definition of Burkitt's Lymphoma from Transcriptional and Genomic Profiling. New England Journal of Medicine, 2006, 354, 2419-2430.	27.0	915
8	Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 13520-13525.	7.1	868
9	The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell, 2003, 3, 185-197.	16.8	848
10	Molecular Diagnosis of Burkitt's Lymphoma. New England Journal of Medicine, 2006, 354, 2431-2442.	27.0	824
11	Concurrent Expression of MYC and BCL2 in Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone. Journal of Clinical Oncology, 2012, 30, 3452-3459.	1.6	824
12	Oncogenic <i>CARD11</i> Mutations in Human Diffuse Large B Cell Lymphoma. Science, 2008, 319, 1676-1679.	12.6	784
13	Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature, 2012, 490, 116-120.	27.8	759
14	A New Immunostain Algorithm Classifies Diffuse Large B-Cell Lymphoma into Molecular Subtypes with High Accuracy. Clinical Cancer Research, 2009, 15, 5494-5502.	7.0	577
15	Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue. Blood, 2014, 123, 1214-1217.	1.4	518
16	Landscape of somatic mutations and clonal evolution in mantle cell lymphoma. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 18250-18255.	7.1	488
17	Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry. Lancet Oncology, The, 2015, 16, 1111-1122.	10.7	483
18	MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma. Blood, 2013, 121, 2253-2263.	1.4	468

#	Article	IF	CITATIONS
19	Immunohistochemical Methods for Predicting Cell of Origin and Survival in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab. Journal of Clinical Oncology, 2011, 29, 200-207.	1.6	426
20	Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction. Blood, 2005, 106, 3183-3190.	1.4	348
21	Cyclin D1-negative mantle cell lymphoma: a clinicopathologic study based on gene expression profiling. Blood, 2005, 106, 4315-4321.	1.4	330
22	Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): a clinicopathological study from the European MCL Network. British Journal of Haematology, 2005, 131, 29-38.	2.5	299
23	BCL2 Expression Is a Prognostic Marker for the Activated B-Cell–Like Type of Diffuse Large B-Cell Lymphoma. Journal of Clinical Oncology, 2006, 24, 961-968.	1.6	277
24	EZH2 mutations are frequent and represent an early event in follicular lymphoma. Blood, 2013, 122, 3165-3168.	1.4	274
25	TRK-Fused Gene (TFG) Is a New Partner of ALK in Anaplastic Large Cell Lymphoma Producing Two Structurally DifferentTFG-ALK Translocations. Blood, 1999, 94, 3265-3268.	1.4	266
26	Cytomorphologic, immunohistochemical, and cytogenetic profiles of follicular lymphoma: 2 types of follicular lymphoma grade 3. Blood, 2002, 99, 3806-3812.	1.4	259
27	Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group. Blood, 2008, 111, 2385-2387.	1.4	220
28	Understanding MYC-driven aggressive B-cell lymphomas: pathogenesis and classification. Blood, 2013, 122, 3884-3891.	1.4	188
29	Pathogenesis of Mantle-Cell Lymphoma: All Oncogenic Roads Lead to Dysregulation of Cell Cycle and DNA Damage Response Pathways. Journal of Clinical Oncology, 2005, 23, 6364-6369.	1.6	186
30	Clinical Impact of the Cell-of-Origin Classification and the <i>MYC</i> / <i>BCL2</i> Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group. Journal of Clinical Oncology, 2017, 35, 2515-2526.	1.6	179
31	Follicular lymphomas with and without translocation t(14;18) differ in gene expression profiles and genetic alterations. Blood, 2009, 114, 826-834.	1.4	177
32	Immunoblastic morphology but not the immunohistochemical GCB/nonGCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHL. Blood, 2010, 116, 4916-4925.	1.4	176
33	High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements with diffuse large B-cell lymphoma morphology. Blood, 2018, 131, 2060-2064.	1.4	167
34	Specific Secondary Genetic Alterations in Mantle Cell Lymphoma Provide Prognostic Information Independent of the Gene Expression–Based Proliferation Signature. Journal of Clinical Oncology, 2007, 25, 1216-1222.	1.6	166
35	Biological characterization of adult MYC-translocation-positive mature B-cell lymphomas other than molecular Burkitt lymphoma. Haematologica, 2014, 99, 726-735.	3.5	157
36	Ki-67 as a prognostic marker in mantle cell lymphoma—consensus guidelines of the pathology panel of the European MCL Network. Journal of Hematopathology, 2009, 2, 103-111.	0.4	149

#	Article	IF	CITATIONS
37	Follicular lymphoma grade 3B is a distinct neoplasm according to cytogenetic and immunohistochemical profiles. Haematologica, 2011, 96, 1327-1334.	3.5	142
38	Mutation and genomic deletion status of <i>ataxia telangiectasia mutated</i> (<i>ATM</i>) and <i>p53</i> confer specific gene expression profiles in mantle cell lymphoma. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 2352-2357.	7.1	138
39	The Ki67 proliferation index is a quantitative indicator of clinical risk in mantle cell lymphoma. Blood, 2006, 107, 3407-3407.	1.4	136
40	Clinical, Immunophenotypic, and Genetic Analysis of Adult Lymphomas With Morphologic Features of Burkitt Lymphoma. American Journal of Surgical Pathology, 2005, 29, 1086-1094.	3.7	135
41	Expression of the FOXP1 transcription factor is strongly associated with inferior survival in patients with diffuse large B-cell lymphoma. Clinical Cancer Research, 2005, 11, 1065-72.	7.0	130
42	A distinctive subtype of t(14;18)-negative nodal follicular non-Hodgkin lymphoma characterized by a predominantly diffuse growth pattern and deletions in the chromosomal region 1p36. Blood, 2009, 113, 1053-1061.	1.4	128
43	Differential Diagnosis Between Classic Hodgkin's Lymphoma, T-Cell-Rich B-Cell Lymphoma, and Paragranuloma by Paraffin Immunohistochemistry. American Journal of Surgical Pathology, 1998, 22, 1184-1191.	3.7	126
44	Genomic DNA-chip hybridization in t(11;14)-positive mantle cell lymphomas shows a high frequency of aberrations and allows a refined characterization of consensus regions. Blood, 2004, 104, 795-801.	1.4	121
45	Cytogenetic Alterations Affecting BCL6 Are Predominantly Found in Follicular Lymphomas Grade 3B with a Diffuse Large B-Cell Component. American Journal of Pathology, 2004, 165, 481-490.	3.8	119
46	Genome-wide analysis of pediatric-type follicular lymphoma reveals low genetic complexity and recurrent alterations of TNFRSF14 gene. Blood, 2016, 128, 1101-1111.	1.4	115
47	Molecular profiling of pediatric mature B-cell lymphoma treated in population-based prospective clinical trials. Blood, 2008, 112, 1374-1381.	1.4	112
48	Genome-wide copy-number analyses reveal genomic abnormalities involved in transformation of follicular lymphoma. Blood, 2014, 123, 1681-1690.	1.4	110
49	Global microRNA expression profiling uncovers molecular markers for classification and prognosis in aggressive B-cell lymphoma. Blood, 2015, 125, 1137-1145.	1.4	110
50	New Molecular Assay for the Proliferation Signature in Mantle Cell Lymphoma Applicable to Formalin-Fixed Paraffin-Embedded Biopsies. Journal of Clinical Oncology, 2017, 35, 1668-1677.	1.6	102
51	A Case of a Diffuse Large B-Cell Lymphoma of Plasmablastic Type Associated With the t(2;5)(p23;q35) Chromosome Translocation. American Journal of Surgical Pathology, 2003, 27, 1473-1476.	3.7	101
52	MINCR is a MYC-induced IncRNA able to modulate MYC's transcriptional network in Burkitt lymphoma cells. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E5261-70.	7.1	91
53	Chromatin conformation analysis of primary patient tissue using a low input Hi-C method. Nature Communications, 2018, 9, 4938.	12.8	89
54	A gene signature that distinguishes conventional and leukemic nonnodal mantle cell lymphoma helps predict outcome. Blood, 2018, 132, 413-422.	1.4	89

#	Article	IF	CITATIONS
55	Sensitivity to PI3K and AKT inhibitors is mediated by divergent molecular mechanisms in subtypes of DLBCL. Blood, 2017, 130, 310-322.	1.4	82
56	Prevalence of epstein-barr virus DNA in different T-cell lymphoma entities in a European population. International Journal of Cancer, 1992, 51, 562-567.	5.1	77
57	MicroRNA profiles of t(14;18)–negative follicular lymphoma support a late germinal center B-cell phenotype. Blood, 2011, 118, 5550-5558.	1.4	77
58	The Stromal Cell Marker SPARC Predicts for Survival in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab. American Journal of Clinical Pathology, 2011, 135, 54-61.	0.7	71
59	bcl-1 REARRANGEMENT AND CYCLIN D1 PROTEIN EXPRESSION IN MANTLE CELL LYMPHOMA. , 1996, 179, 238-242.		70
60	Mutations of MAP2K1 are frequent in pediatric-type follicular lymphoma and result in ERK pathway activation. Blood, 2017, 130, 323-327.	1.4	69
61	<i>TP53</i> mutation and survival in aggressive B cell lymphoma. International Journal of Cancer, 2017, 141, 1381-1388.	5.1	69
62	The mutational landscape of Burkitt-like lymphoma with 11q aberration is distinct from that of Burkitt lymphoma. Blood, 2019, 133, 962-966.	1.4	69
63	Accurate Classification of Diffuse Large B-Cell Lymphoma into Germinal Center and Activated B-Cell Subtypes Using a Nuclease Protection Assay on Formalin-Fixed, Paraffin-Embedded Tissues. Clinical Cancer Research, 2011, 17, 3727-3732.	7.0	68
64	A 3-cM commonly deleted region in 6q21 in leukemias and lymphomas delineated by fluorescence in situ hybridization. Genes Chromosomes and Cancer, 2000, 27, 52-58.	2.8	67
65	Identification of Primary Mediastinal Large B-cell Lymphoma at Nonmediastinal Sites by Gene Expression Profiling. American Journal of Surgical Pathology, 2015, 39, 1322-1330.	3.7	63
66	Adult high-grade B-cell lymphoma with Burkitt lymphoma signature: genomic features and potential therapeutic targets. Blood, 2017, 130, 1819-1831.	1.4	62
67	B-cell receptor–driven MALT1 activity regulates MYC signaling in mantle cell lymphoma. Blood, 2017, 129, 333-346.	1.4	57
68	A new biologic prognostic model based on immunohistochemistry predicts survival in patients with diffuse large B-cell lymphoma. Blood, 2012, 120, 2290-2296.	1.4	53
69	A modular transcriptome map of mature B cell lymphomas. Genome Medicine, 2019, 11, 27.	8.2	51
70	Understanding MYC-driven aggressive B-cell lymphomas: pathogenesis and classification. Hematology American Society of Hematology Education Program, 2013, 2013, 575-583.	2.5	46
71	Differential effect of epigenetic alterations and genomic deletions of CDK inhibitors [p16(INK4a),p15(INK4b),p14(ARF)] in mantle cell lymphoma. Genes Chromosomes and Cancer, 2006, 45, 203-210.	2.8	45
72	Loss of HLA-DR expression and immunoblastic morphology predict adverse outcome in diffuse large B-cell lymphoma - analyses of cases from two prospective randomized clinical trials. Haematologica, 2009, 94, 1569-1580.	3.5	44

#	Article	IF	CITATIONS
73	MAPK and JAK-STAT pathways dysregulation in plasmablastic lymphoma. Haematologica, 2021, 106, 2682-2693.	3.5	44
74	Presence of Preserved Reactive Germinal Centers in Follicular Lymphoma Is a Strong Histopathologic Indicator of Limited Disease Stage. American Journal of Surgical Pathology, 2005, 29, 1661-1664.	3.7	43
75	Aggressive Bâ€cell lymphomas in the update of the 4th edition of the World Health Organization classification of haematopoietic and lymphatic tissues: refinements of the classification, new entities and genetic findings. British Journal of Haematology, 2017, 178, 871-887.	2.5	41
76	Chromosomal abnormalities in nodal and extranodal CD30+ anaplastic large cell lymphomas: Infrequent detection of the t(2;5) in extranodal lymphomas. , 1998, 22, 114-121.		40
77	A biological role for deletions in chromosomal band 13q14 in mantle cell and peripheral t-cell lymphomas?. , 1999, 26, 210-214.		36
78	Loss of Fas (CD95/APO-1) Regulatory Function Is an Important Step in Early MALT-Type Lymphoma Development. Laboratory Investigation, 2001, 81, 977-986.	3.7	35
79	Diffuse Large B-cell Lymphomas of Immunoblastic Type Are a Major Reservoir for MYC-IGH Translocations. American Journal of Surgical Pathology, 2015, 39, 61-66.	3.7	34
80	Gene expression profiling reveals a close relationship between follicular lymphoma grade 3A and 3B, but distinct profiles of follicular lymphoma grade 1 and 2. Haematologica, 2018, 103, 1182-1190.	3.5	34
81	The heterogeneity of follicular lymphomas: from early development to transformation. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2016, 468, 127-139.	2.8	31
82	FOXP1 expression is a prognostic biomarker in follicular lymphoma treated with rituximab and chemotherapy. Blood, 2018, 131, 226-235.	1.4	31
83	A Diagnostic Approach to the Identification of Burkitt-like Lymphoma With 11q Aberration in Aggressive B-Cell Lymphomas. American Journal of Surgical Pathology, 2021, 45, 356-364.	3.7	30
84	Non-random integration of epstein-barr virus in lymphoblastoid cell lines. Genes Chromosomes and Cancer, 1993, 8, 38-48.	2.8	29
85	Primary Pulmonary Synovial Sarcoma: A Rare Primary Pulmonary Tumor. Lung, 2014, 192, 211-214.	3.3	28
86	Clinical relevance of molecular characteristics in Burkitt lymphoma differs according to age. Nature Communications, 2022, 13, .	12.8	28
87	Cyclin D1-CDK4 activity drives sensitivity to bortezomib in mantle cell lymphoma by blocking autophagy-mediated proteolysis of NOXA. Journal of Hematology and Oncology, 2018, 11, 112.	17.0	26
88	A novel lymphoma-associated macrophage interaction signature (LAMIS) provides robust risk prognostication in diffuse large B-cell lymphoma clinical trial cohorts of the DSHNHL. Leukemia, 2020, 34, 543-552.	7.2	26
89	Molecular and functional profiling identifies therapeutically targetable vulnerabilities in plasmablastic lymphoma. Nature Communications, 2021, 12, 5183.	12.8	26
90	Validation of the <scp>MCL</scp> 35 gene expression proliferation assay in randomized trials of the European Mantle Cell Lymphoma Network. British Journal of Haematology, 2019, 184, 616-624.	2.5	25

#	Article	IF	CITATIONS
91	Commentary on the WHO classification of tumors of lymphoid tissues (2008): indolent B cell lymphomas. Journal of Hematopathology, 2009, 2, 77-81.	0.4	24
92	The exomic landscape of t(14;18)â€negative diffuse follicular lymphoma with 1p36 deletion. British Journal of Haematology, 2018, 180, 391-394.	2.5	24
93	A 70% cut-off for MYC protein expression in diffuse large B cell lymphoma identifies a high-risk group of patients. Haematologica, 2020, 105, 2667-2670.	3.5	20
94	Advanced patient age at diagnosis of diffuse large B-cell lymphoma is associated with molecular characteristics including ABC-subtype and high expression of MYC. Leukemia and Lymphoma, 2018, 59, 1213-1221.	1.3	18
95	Rituximab plus high-dose chemotherapy (MegaCHOEP) or conventional chemotherapy (CHOEP-14) in young, high-risk patients with aggressive B-cell lymphoma: 10-year follow-up of a randomised, open-label, phase 3 trial. Lancet Haematology,the, 2021, 8, e267-e277.	4.6	18
96	Epstein–Barr virus status of sporadic Burkitt lymphoma is associated with patient age and mutational features. British Journal of Haematology, 2022, 196, 681-689.	2.5	18
97	Cene Expression Signatures for the Accurate Diagnosis of Peripheral T-Cell Lymphoma Entities in the Routine Clinical Practice. Journal of Clinical Oncology, 2022, 40, 4261-4275.	1.6	17
98	Numerical and Structural Genomic Aberrations Are Reliably Detectable in Tissue Microarrays of Formalin-Fixed Paraffin-Embedded Tumor Samples by Fluorescence In-Situ Hybridization. PLoS ONE, 2014, 9, e95047.	2.5	16
99	The impact of SOCS1 mutations in diffuse large Bâ€cell lymphoma. British Journal of Haematology, 2019, 187, 627-637.	2.5	15
100	Optimized protocol for metabolomic and lipidomic profiling in formalin-fixed paraffin-embedded kidney tissue by LC-MS. Analytica Chimica Acta, 2020, 1134, 125-135.	5.4	15
101	Commentary on the WHO classification of tumors of lymphoid tissues (2008): aggressive B-cell lymphomas. Journal of Hematopathology, 2009, 2, 83-87.	0.4	14
102	Dual targeting of MCL1 and NOXA as effective strategy for treatment of mantle cell lymphoma. British Journal of Haematology, 2017, 177, 557-561.	2.5	14
103	New targeted therapies for malignant lymphoma based on molecular heterogeneity. Expert Review of Hematology, 2017, 10, 39-51.	2.2	14
104	Diffuse large B-cell lymphoma cell-of-origin classification using the Lymph2Cx assay in the context of BCL2 and MYC expression status. Leukemia and Lymphoma, 2016, 57, 717-720.	1.3	13
105	Differential expression of long nonâ€coding <scp>RNA</scp> s are related to proliferation and histological diversity in follicular lymphomas. British Journal of Haematology, 2019, 184, 373-383.	2.5	12
106	Mantle cell lymphomas with concomitant MYC and CCND1 breakpoints are recurrently TdT positive and frequently show high-grade pathological and genetic features. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2021, 479, 133-145.	2.8	12
107	Increased cFLIP expression in thymic epithelial tumors blocks autophagy via NF-ήB signalling. Oncotarget, 2017, 8, 89580-89594.	1.8	12
108	The Hans classificator does not predict outcome in diffuse large B cell lymphoma in a large multicenter retrospective analysis of R-CHOP treated patients. Leukemia Research, 2012, 36, 544-545.	0.8	11

#	Article	IF	CITATIONS
109	The "Burkitt-like―immunophenotype and genotype is rarely encountered in diffuse large B cell lymphoma and high-grade B cell lymphoma, NOS. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2021, 479, 575-583.	2.8	11
110	Enzymatically Modified Lowâ€Density Lipoprotein Is Present in All Stages of Aortic Valve Sclerosis: Implications for Pathogenesis of the Disease. Journal of the American Heart Association, 2015, 4, e002156.	3.7	10
111	The impact of <scp>SAMHD1</scp> expression and mutation status in mantle cell lymphoma: An analysis of the <scp>MCL</scp> Younger and Elderly trial. International Journal of Cancer, 2021, 148, 150-160.	5.1	10
112	Tubular breast cancer. A retrospective study. Anticancer Research, 2014, 34, 3647-56.	1.1	9
113	Experience with telepathology in combination with diagnostic assistance systems in countries with restricted resources. Journal of Telemedicine and Telecare, 2020, 26, 488-494.	2.7	8
114	Genetic Rearrangements of FOXP1 Are Restricted to a Subset of Agressive B Cell Lymphoma with Extranodal Presentation Blood, 2005, 106, 2837-2837.	1.4	7
115	A cytomorphological and immunohistochemical profile of aggressive B-cell lymphoma: high clinical impact of a cumulative immunohistochemical outcome predictor score. Journal of Hematopathology, 2009, 2, 187-194.	0.4	6
116	Human Endogenous Retroviruses: Residues of Ancient Times Are Differentially Expressed in Crohn's Disease. Inflammatory Intestinal Diseases, 2018, 3, 125-137.	1.9	6
117	Interphase cytogenetics of glioblastoma and gliosarcoma. Acta Neuropathologica, 1994, 88, 420-425.	7.7	5
118	Genomic deletion and promoter methylation status of Hypermethylated in Cancer 1 (HIC1) in mantle cell lymphoma. Journal of Hematopathology, 2008, 1, 85-95.	0.4	4
119	bclâ€l REARRANGEMENT AND CYCLIN D1 PROTEIN EXPRESSION IN MANTLE CELL LYMPHOMA. Journal of Pathology, 1996, 179, 238-242.	4.5	4
120	ls Mistletoe Treatment Beneficial in Invasive Breast Cancer? A New Approach to an Unresolved Problem. Anticancer Research, 2018, 38, 1585-1593.	1.1	4
121	Cytokeratin expression in plasmablastic lymphoma – a possible diagnostic pitfall in the routine workâ€up of tumours. Histopathology, 2021, 78, 831-837.	2.9	3
122	Mantle cell lymphoma. , 2001, , 154-167.		2
123	Late lung metastasis of primary endometrial cancer. Memo - Magazine of European Medical Oncology, 2012, 5, 262-265.	0.5	2
124	Burkitt lymphoma and diffuse large B-cell lymphoma: a unique case of a composite lymphoma of different clonal origin. Leukemia and Lymphoma, 2018, 59, 249-252.	1.3	2
125	The broad and challenging landscape of extranodal lymphoproliferations. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2020, 476, 633-646.	2.8	2
126	Pathology and Molecular Pathogenesis of DLBCL and Related Entities. Methods in Molecular Biology, 2019, , 41-73.	0.9	2

#	Article	IF	CITATIONS
127	Concurrent BCL2 and MYC Protein Expression by Immunohistochemistry Determines Clinical Outcome In DLBCL Patients Treated with R-CHOP. Blood, 2010, 116, 2005-2005.	1.4	2
128	Conventional Immunochemotherapy (R-CHOEP) Vs High-Dose Immunochemotherapy (R-MegaCHOEP) in Younger Patients with High-Risk Aggressive B-Cell Lymphoma: 10-Year Long-Term Follow-up of a German Lymphoma Alliance (GLA) Study. Blood, 2019, 134, 1589-1589.	1.4	2
129	Identification of a miRNA based model to detect prognostic subgroups in patients with aggressive B-cell lymphoma. Leukemia and Lymphoma, 2021, 62, 1107-1115.	1.3	2
130	A new tool for bile duct tissue sampling: ex vivo clinical evaluation of intraductal cryobiopsy for cholangioscopy. Endoscopy International Open, 2022, 10, E809-E814.	1.8	2
131	Differentiation of low-grade non-Hodgkin's lymphomas using paraffin sections by image processing. , 1998, 34, 75-81.		1
132	Central nervous system lymphoma. , 2001, , 200-214.		1
133	Gadolinium Deposits Could Influence the Course of Encapsulating Peritoneal Sclerosis. Peritoneal Dialysis International, 2014, 34, 561-565.	2.3	1
134	PARP14 Is a Novel Therapeutic Target in STAT6 mutant Follicular Lymphoma. Blood, 2018, 132, 2842-2842.	1.4	1
135	Chromosomal Imbalances in Germinal Center B-Cell-Like and Activated B-Cell-Like Diffuse Large B-Cell Lymphoma Influence Gene Expression Signatures and Improve Gene Expression-Based Survival Prediction(the First Two Authors Contributed Equally to This Work) Blood, 2004, 104, 415-415.	1.4	1
136	Clinical Validation of MCL35 in Mantle Cell Lymphoma Patients ≥65 Years Receiving Bendamustine-Rituximab. Blood, 2021, 138, 3517-3517.	1.4	1
137	Gene expression profiling in lymphoid malignancies. , 2001, , 162-186.		0
138	Hodgkin's lymphoma. , 2001, , 89-110.		0
139	Pathology and cytogenetics. , 2001, , 12-18.		0
140	Follicular lymphoma. , 2001, , 111-125.		0
141	MALT lymphoma and other marginal zone lymphomas. , 2001, , 126-140.		0
142	Small lymphocytic lymphoma and its variants. , 2001, , 141-153.		0
143	Diffuse large B-cell lymphoma. , 2001, , 168-181.		0
144	Burkitt's and lymphoblastic lymphomas. , 2001, , 182-199.		0

#	Article	IF	CITATIONS
145	T-cell lymphoma. , 2001, , 215-232.		0
146	Cutaneous lymphoma. , 2001, , 233-251.		0
147	Lymphoma in the immunosuppressed. , 2001, , 252-265.		0
148	Elevated serum free light chains do not predict outcome of elderly patients with aggressive <scp>CD</scp> 20 ⁺ B ell lymphomas. British Journal of Haematology, 2014, 167, 430-434.	2.5	0
149	Lymphoproliferations at extranodal sites: a morphologically, genetically, and clinically diverse group of neoplasms with overlapping features. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2020, 476, 629-631.	2.8	0
150	Cyclin D1 Over-Expressing Mantle Cell Lymphoma Cells Are Hypersensitive to Inhibition of Fatty Acid Synthase (FASN). Blood, 2011, 118, 1656-1656.	1.4	0
151	Clinicogenetic Risk Models in Patients Randomized to Receive Consolidative Autologous Stem-Cell Transplantation after Frontline R-CHOP for Advanced Follicular Lymphoma: An Analysis from the GLSC2000 Trial. Blood, 2018, 132, 4096-4096.	1.4	0
152	Adding Etoposide to R-CHOP (R-CHOEP) Does Not Significantly Increase the Risk of Secondary Neoplasms in Patients with Aggressive B-Cell Lymphoma - Results from Randomized Phase 3 Trials of the German Lymphoma Alliance (GLA). Blood, 2020, 136, 5-6.	1.4	0